Researchsemaglutideglp-1 receptor agonistsmenopauseclimacteric

Climacteric review maps GLP-1 use in perimenopause and early postmenopause

Authors flag unresolved questions about long-term safety, bone and muscle effects, and interactions with menopausal hormone therapy.

By Priya Raman · Science Reporter

Oct 7 20:00 ETSource: Climacteric : the journal of the International Menopause Society

The wire

01A review in Climacteric summarizes GLP-1 receptor agonist evidence in midlife women, covering visceral adiposity, glycemic control, lipid profiles, hepatic steatosis and cardiovascular outcomes.
02Clinicians treating perimenopausal patients get a consolidated reference, including preliminary experimental signals of complementary effects when GLP-1 RAs are combined with menopausal hormone therapy.
03The authors state menopause-specific evidence remains limited; this is a narrative review, not new trial data, and combination safety with hormone therapy is undetermined.

From the source

GLP-1 receptor agonists in perimenopause and early postmenopause: clinical role, cardiometabolic benefits and knowledge gaps
Climacteric : the journal of the International Menopause Society · 2026 Oct 8 · Ozcivit Erkan IB, Senturk LM, Erel CT et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42847987/